HIRUDIN LEECH, RECOMBINANT
HIRUDIN LEECH, RECOMBINANT structure
|
Common Name | HIRUDIN LEECH, RECOMBINANT | ||
|---|---|---|---|---|
| CAS Number | 8001-27-2 | Molecular Weight | 7027 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C287H440N80O110S6 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
Use of HIRUDIN LEECH, RECOMBINANTHirudin is a Thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others[1]. |
| Name | HIRUDIN |
|---|---|
| Synonym | More Synonyms |
| Description | Hirudin is a Thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Hirudin 抑制凝血酶活性，剥夺凝血酶裂解纤维蛋白原的能力，阻止纤维蛋白的形成及内外凝血通路中纤维蛋白单体的交联聚合过程[1]。 Hirudin 通过拮抗凝血酶，减少人微血管内皮细胞凋亡，抑制 p-JAK2 的表达[1]。 Hirudin 抑制 VEGF-Notch 通路和人微血管内皮细胞增殖在高剂量时[1]。 Hirudin (3-10 mg/mL) 可逆转 TGF-β1 引起的 HK-2 细胞异常增殖和纤维化[1]。 Hirudin 剂量依赖性地抑制血管紧张素 II 诱导的心肌成纤维细胞，抑制氧化应激，调节纤维相关因子，抑制 ERK1/2 通路[1]。 |
| In Vivo | Hirudin 增加大鼠随机皮瓣的生存能力，减少炎症反应[1]。 Hirudin 促进激光手术后 SD 大鼠的创面愈合[1]。 Hirudin (10 和 15 mg/kg；灌胃，每天 1 次，持续 21 天) 改善肾间质纤维化来减少肾小管损伤和炎症在单侧输尿管梗阻 (UUO) 小鼠模型中[2]。 Animal Model: Male balb/c mice with underwent unilateral ureteral ligation (UUO)[2] Dosage: 10 and 15 mg/kg Administration: Oral gavage; 10 and 15 mg/kg, once daily for 21 days Result: Reduced renal damages and suppressed the upregulation of α-SMA, collagen deposition in UUO mice. Increased the level of fibrosis (collagen-I, FN, α-SMA), N-cad, slug and E-cad in UUO mice. Decreased the level of IL-1β, IL-6 and TNF-α, apoptosis of renal tubular cells in UUO mice. Decreased the expression of inflammatory factors, the occurrence of EMT, the incidence of fibrosis and the apoptosis of TGF-β-induced renal tubular epithelial cell. |
| References |
| Molecular Formula | C287H440N80O110S6 |
|---|---|
| Molecular Weight | 7027 |
| Appearance of Characters | lyophilized powder |
| Storage condition | −70°C |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
|---|---|
| Safety Phrases | 22-24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | MR8440000 |
|
Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage.
Brain 132 , 26-36, (2009) Proteases such as matrix metalloproteinases (MMPs) and thrombin are implicated in intracerebral haemorrhage (ICH) but their interactions amongst one another and interdependency remain to be defined. T... |
|
|
TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells.
J. Immunol. 196 , 832-45, (2016) Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy with severe renal injury secondary to an overactive alternative complement pathway (AP). aHUS episodes are often initiated or ... |
|
|
Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.
Stroke 40(5) , 1864-9, (2009) Activated protein C (APC), a protease with anticoagulant and cytoprotective activities, protects neurons and endothelium from ischemic injury. Drotrecogin-alfa activated, a hyperanticoagulant form of ... |
| EINECS 232-279-1 |